Current issues in the management of differentiated thyroid cancer

Nuclear Medicine Communications

Volumn 25, Issue 9, 2004, Pages 873-881

  Mallick, Ujjal K ^a,b   Charalambous, Haris ^a  

^a Northern Centre for Cancer Care   (United Kingdom)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Differentiated thyroid cancer; Radioiodine; Recombinant human TSH; Thyroglobulin

Indexed keywords

AMIFOSTINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; IODINE 123; IODINE 131; ISOTRETINOIN; LANREOTIDE Y 90; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY; OCTREOTIDE; PROTEASOME INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; RECEPTOR BLOCKING AGENT; RECOMBINANT THYROTROPIN; SODIUM IODIDE SYMPORTER; STEROID; THALIDOMIDE; THYROID HORMONE; THYROXINE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ACUTE TOXICITY; ALOPECIA; BONE MARROW SUPPRESSION; BONE PAIN; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOTOXICITY; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG UPTAKE; EDEMA; GASTROINTESTINAL TOXICITY; HEADACHE; HEMIPLEGIA; HUMAN; HYPOTHYROIDISM; LOW DRUG DOSE; LUNG METASTASIS; NAUSEA; OSTEOSARCOMA; RESPIRATORY FAILURE; SALIVARY GLAND DISEASE; SIDE EFFECT; SOFT TISSUE METASTASIS; THYROID CANCER;

CLINICAL TRIALS; HUMANS; IODINE RADIOISOTOPES; NEOPLASM RECURRENCE, LOCAL; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RADIOPHARMACEUTICALS; RISK ASSESSMENT; RISK FACTORS; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 4444371551     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006231-200409000-00003     Document Type: Conference Paper

References (74)

1. Coleman PM, Babb P, Damiecki P, Groslaude P, Honjo S, Jones J, et al. Cancer Survival Trends in England and Wales 1987-1995: Deprivation and NHS Region. (Series SMPS No. 61.) London: Stationery Office Ltd; 1999; pp. 471-478.
2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A national cancer data base report on 53, 856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 1998; 83:2638-2648.
3. Cady B, Rossi R. An expanded view of risk group definition in differentiated thyroid carcinoma. Surgery 1988; 104:947-953.
4. Cady B. our AMES is true: how an old concept still hits the mark or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg 1997; 174:462-446.
5. Sanders LE, Cady B. Differentiated thyroid cancer. Re-examination of risk groups and outcome of treatment. Arch Surg 1998; 133:419-425.
6. Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 1995; 118:1131-1138.
7. Hay ID, McConahey WM, Goellner JR. Managing patients with papillary thyroid carcinoma: Insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000. American Clinical and Climatological Association 2002; 113:241-260.
8. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418-428.
9. Mazzaferri E, Kloos R. Current approaches to primary therapy for papillary and follicular thyroid cancer. Clinical review 128. J Clin Endocrinol Metab 2001; 86:1447-1463.
10. Kebebew E, Clark OH. Differentiated thyroid cancer 'complete' rational approach. World J Surg 2000; 24:942-951.
11. De-Groot LJ, Kaplan EL, McCormick M, Straus FH. Natural history and course of papillary thyroid cancer. J Clin Endocrinol Metab 1990; 71:414-424.
12. Mazzaferri EL, Robbins RJ, Braverman LE, Pacini F, Haugen B, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low risk patients with papillary thyroid carcinoma. [Authors' response] J Clin Endocrinol Metab 2003; 88:4508-4509.
13. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004; 151:155-156.
14. NCCN Thyroid Carcinoma Guidelines, 2001. www.NCCN.org
15. AACE. Clinical practice guidelines for the management of thyroid carcinoma, website http:/www.aace.com/guidelines/thyroidcancer.html
16. Hodgson DC, Brierley JD, Tsang RW, Panzarella T. Prescribing I-131 iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay. Radiother Oncol 1998; 47:325-330.
17. 131I dose in differentiated thyroid cancer. Clin Endocrinol (Oxford) 2000; 52:765-773.
18. Johansen K, Woodhouse NJ, Odugbesan O. Comparing 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med 1991; 32:252-254.
19. 131I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 1996; 77:2574-2580.
20. Sirisalipoch S, Buachum V, Pasawang P, Tepmongkol S. Prospective randomised trial for the evaluation of the efficacy of low vs high dose I-131 for post operative remnant ablation in differentiated thyroid cancer. World J Nucl Med 2004; 3(suppl 1).
21. Maxon H, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS, et al. Radioiodine-131 therapy for well differentiated thyroid cancer - a quantitative radiation dosimetric approach: Outcome and validation in 85 patients. J Nucl Med 1992; 33:1132-1136.
22. 131I: A comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002; 87:4063-4068.
23. Barbaro D, Boni G, Mencci G, Simi U, Lapi P, Orsini P, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 2003; 88:4110-4115.
24. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002; 87:1490-1498.
25. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A, et al. Diagnostic 131-iodine whole body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002; 87:1499-1501.
26. Cailleux AF, Baudin E, Travagli JP, Picard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?. J Clin Endocrinol Metab 2000; 85:175-178.
27. 131I whole body scan after recombinant human TSH stimulation in the follow-up of low risk patients with differentiated thyroid cancer. Eur J Endocrinol 2003; 184:19-24.
28. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003; 88:3668-3673.
29. Haugen BR, Pacini F, Reiners C, Schlumberger M, Landenson PW, Sheman SI, et al. A comparison of recombinant thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84:3877-3885.
30. Robbins RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001; 86:619-625.
31. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997; 337:888-896.
32. Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient by itself to monitor for residual thyroid carcinoma. J Clin Endocrinol Metab 2002; 87:3242-3247.
33. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT. Clinical comparison of whole body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid 2002; 12:37-42.
34. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C, et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the post surgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001; 86:5686-5690.
35. 131I scanning. J Clin Endocrinol Metab 2002; 87:1486-1489.
36. Mazzaferri EL, Robbins RJ, Spencer CA, Braveman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88:1433-1441.
37. Spencer C, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyroglobulin assays. Clin Chem 1996; 42:164-173.
38. Robins R, Larson SM, Sinha N, Shaha A, Divgi C, Pentlow KS, et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med 2002; 43:1482-1489.
39. Robbins R. Recombinant human thyrotropin and thyroid cancer management - clinical review 56. J Clin Endocrinol Metabol 2003; 88:1933-1938.
40. Lippi F, Capezzone M, Angelina F, Taddei D, Molinaro E, Pinchera A, Pacini F. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. Eur J Endocrinol 2001; 144:5-11.
41. Berg G, Lindstedt F, Suurkula M, Jansson S. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest 2002; 25:44-52.
42. 131I. J Nucl Med 2003; 44:1065-1068.
43. Schlumberger M, Ricard M, Pacini F. Clinical use of recombinant human TSH in thyroid cancer patients. Eur J Endocrinol 2000; 143:557-563.
44. Durski JM, Weigel RJ, McDougall IR. Recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer. Nucl Med Commun 2000; 21:521-528.
45. Vargas GE, Uy H, Bazan C, Guise TA, Bruder JM. Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain. J Clin Endocrinol Metab 1999; 84:3867-3871.
46. Goffman T, Ioffe V, Tuttle M, Bowers JT, Mason ME. Near-lethal respiratory failure after recombinant human thyroid-stimulating hormone use in a patient with metastatic thyroid carcinoma. Thyroid 2003; 13:827-830.
47. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Sir PA, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement and prognostic significance in patients with differentiated thyroid cancer. J Clin Endocrinol Metab 1998; 83:1121.
48. Maxon HR, Thomas SR, Boehringer A, Drilling J, Sparkling MI, Sparks JC, Chen IW, et al. Low iodine diet in I-131 ablation of thyroid remnants. Clin Nucl Med 1983; 8:123-126.
49. Dohan O, De la Viaja A, Paroder V, Riedel C, Artani M, Reed M, Ginter CA, Carrasco N. The sodium/iodide symporter (NIS): characterization, regulation and medical significance. Endocrinol Rev 2003; 24:48-77.
50. Gemsenjager E. Thyroglobulin-positive, radioiodine-negative thyroid cancer. [Letter] Thyroid 2003; 13:833-834.
51. 131 scan: investigation and management. Clin Oncol 2002; 14:435-436.
52. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995; 80:1488-1492.
53. Schlumberger M, Mancusi F, Baudin E, Pacini F. I-131 therapy for elevated thyroglobulin levels. Thyroid 1997; 7:273-276.
54. 131I activities versus untreated patients. J Clin Endocrinol Metab 2001; 86:4092-4097.
55. Mazzaferri E. Treating high thyroglobulin with radioiodine: a magic bullet or a shot in the dark? [Editorial] J Clin Endocrinol Metab 1995; 80:1485-1487.
56. McDougal IR. I-131 treatment of I-131 negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated? Thyroid 1997; 7:699-672.
57. Fatourechi V, Hay ID, Javedan H, Wiseman GA, Mullan BP, Gorman CA. Lack of impact of radioiodine therapy in Tg-positive, diagnostic whole body scan negative patients with follicular cell derived thyroid cancer. J Clin Endocrinol Metab 2002; 87:1521-1526.
58. Wartofsky L. Management of patients with scan negative; thyroglobulin positive differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998; 83:4195-4199.
59. Van Tol KM, Jager PL, de Vries EG, Piers DA, Boezen HM, Sluiter WJ, et al. Outcomes in patients with differentiated thyroid cancer with negative Diagnostic whole body Scanning and detectable stimulated thyroglobulin. Eur J of Endorinol 2003; 148:589-596.
60. Droz JP, Schlumberger M, Rougier P, Ghosn M, Gardet P, Parmentier C. Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 1990; 76:480-483.
61. Saller B. Treatment with cytotoxic drugs. In: Biersack HJ, Grunwald F (editors). Thyroid Cancer. Springer Verlag; 2002.
62. Williams SD, Birch R, Einhorn LH. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986; 70:405-407.
63. Judson I, Radford JA, Harris M, Blay JY, Van Hoesel Q, Le Cesne, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue and bone sarcoma. Eur J Cancer 2001; 37:870-877.
64. Santini F, Bottici V, Elisei R, Montanelli L, Mazzeo S, Basolo F, et al. Cytotoxic effects of carboplatinum and epirubicin in the setting of elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. J Clin Endocrinol Metab 2002; 87:4140-4145.
65. Morris JC, Kim CK, Padilla ML, Mechanink JL. Conversion of non-iodine-concentrating differentiated thyroid carcinoma metastases into iodine concentrating foci after anticancer chemotherapy. Thyroid 1997; 7:63-66.
66. Christian JA, Cook GJ, Harmer C. Indium-111 labelled octreotide scintigraphy in the diagnosis and management of non-iodine avid metastatic carcinoma of the thyorid. Br J Cancer 2003; 89:258-261.
67. Simon D, Korber C, Krausch M, Segering T, Groth P, Gorges R, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imag 2002; 29:775-782.
68. Braga-Basaria M, Ringel MD. Beyond radioiodine: A review of potential new therapeutic approaches for thyroid cancer. J Clin Endocrinol Metab 2002; 88:1947-1960.
69. Smit JW, Schroeder-van der Elst JP, Karperien M, Que I, van der Plumijm G, Goslings B, et al. Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line. Thyroid 2000; 10:939-943.
70. Smit JW, Schroeder-van der Elst JP, Karperien M, Que I, Romijn JA, van der Heide D. Expression of the human sodium/iodide symporter (hNIS) in xenotransplanted human thyroid carcinoma. Exp Clin Endocrinol Diabetes 2001; 109:52-55.
71. Boland A, Magnon C, Filetti S, Bidart JM, Schlumberger M, Yeh P, Perricandet M. Transposition of the thyroid iodide uptake and organification system in non-thyroid tumour cells by adenoviral vector-mediated gene transfers. Thyroid 2002; 12:19-26.
72. Spitzweg C, Harrington KJ, Pinke LA, Vile RG, Morris JC. The sodium iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab 2001; 86:3327-3335.
73. Scholz V, Cengic N, Goke J, Morris C, Spitzweg C. Dexamethasone enhances the cytotoxic effect of radioiodine therapy in prostate cancer cells expressing the sodium iodide symporter. J Clin Endocrinol Metab 2004; 89:1108-1116.
74. Gabler B, Aicher T, Heiss P, Senekowitsch-Schmidtke R. Growth inhibition of human papillary thyroid carcinoma cells and multicellular spheroids by anti-EGF-receptor antibody. Anticancer Res 1997; 17:3157-3159.